Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$87.73 USD

87.73
4,499,207

-1.77 (-1.98%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $87.73 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare

Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare

Edwards (EW) States Long-Term Strategy, Provides 2022 View

Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.

Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up

Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.

Edwards Lifesciences (EW) Tops Q3 Earnings Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.89% and -0.92%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More

With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.

OCPNY or EW: Which Is the Better Value Stock Right Now?

OCPNY vs. EW: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands

The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands

Mark Vickery headshot

Top Analyst Reports for Edwards Lifesciences, DexCom & Twitter

Today's Research Daily features new research reports on 12 major stocks, including Edwards Lifesciences Corporation (EW), DexCom, Inc. (DXCM), and Twitter, Inc. (TWTR).

Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?

Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable

Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.

The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences

Sheraz Mian headshot

Top Analyst Reports for Facebook, AbbVie & 3M

Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), AbbVie Inc. (ABBV), and 3M Company (MMM).

Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?

Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS

Sheraz Mian headshot

Top Research Reports for Costco, Altria & Edwards Lifesciences

Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale (COST), Altria Group, Inc. (MO), and Edwards Lifesciences (EW).

Urmimala Biswas headshot

3 Medical Instruments Stocks Countering Industry Headwinds

The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most. However, falling demand for COVID-19 tests might disrupt the trend.

Hill-Rom (HRC) Q3 Earnings Top Estimates, 2021 Guidance Up

Hill-Rom (HRC) reports better-than-expected revenues for third-quarter fiscal 2021 with strong segmental performance driving the top line.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up

Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.

Edwards Lifesciences (EW) Q2 Earnings and Revenues Surpass Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 16.36% and 7.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Edwards Lifesciences (EW) Q2 Earnings?

Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.